Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

24 Jul 2026, 10:45 UTC · 59m ago

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

What the story claims

1 claim · each scored for market impact

What matters in this story

1
Merck has entered into voluntary licensing agreements covering 129 countries for HIV treatments. — While expanding access to medication is a positive ESG signal, voluntary licensing often involves sharing IP, which can slightly limit high-margin exclusivity in those specific regions.
+0.10

Which stocks this story touches

How each ticker is affected

MRK+0.50
The company is expanding the reach of its HIV treatments through voluntary licensing agreements in 129 countries.

Read original · https://www.businesswire.com/news/home/20260723155636/en/Merck-Announces-Initial-Access-Plans-for-Alimatravir-an-Investigational-Once-Monthly-Oral-HIV-Pre-Exposure-Prophylaxis-in-Phase-3-Development/

6 related stories

Reuters
56m ago
Merck licenses experimental HIV pill to generic makers in 129 countries
- global health
- hiv
- licensing
Read

Merck Announces Initial Ac… — MRK +0.50 | NewsImpactScreener

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

What matters in this story

How each ticker is affected

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

What matters in this story

How each ticker is affected

Merck licenses experimental HIV pill to generic makers in 129 countries

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

AstraZeneca 'magic' faces rare test after trial failure, share slide

AHF at AIDS 2026 Conference: AIDS Isn't Over—and Syphilis Is Surging

Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial

$PODD Fraud Notification: Insulet Sued for Fraud Over Misrepresentations about its Safety Issues – Investors Notified to Contact BFA Law

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

What matters in this story

How each ticker is affected

Next reads from the same story arc

Merck licenses experimental HIV pill to generic makers in 129 countries

Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development

What matters in this story

How each ticker is affected

Next reads from the same story arc

Merck licenses experimental HIV pill to generic makers in 129 countries

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

AstraZeneca 'magic' faces rare test after trial failure, share slide

AHF at AIDS 2026 Conference: AIDS Isn't Over­—and Syphilis Is Surging

Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial

$PODD Fraud Notification: Insulet Sued for Fraud Over Misrepresentations about its Safety Issues – Investors Notified to Contact BFA Law

AHF at AIDS 2026 Conference: AIDS Isn't Over—and Syphilis Is Surging